How to Take Progesterone: Oral, Vaginal, and More

Progesterone can be taken by mouth, inserted vaginally, injected into muscle, applied to the skin, or administered rectally or sublingually, and the route your provider chooses depends on why you need it. Each delivery method sends progesterone through your body in a meaningfully different way, producing different blood levels, different tissue concentrations, and different side-effect profiles. The choice is rarely just about convenience; it shapes how well the hormone reaches the tissue that actually needs it.

Why the Route Matters So Much

When you swallow a progesterone capsule, it passes through your digestive tract and liver before reaching the rest of your body. That first pass through the liver breaks down a large share of the hormone and converts it into metabolites, some of which have their own effects, including drowsiness. A single oral dose produces blood levels of progesterone and its sedating metabolite allopregnanolone that are roughly two to three times higher than what your body makes on its own during the same timeframe.¹ When progesterone is given vaginally, it largely bypasses the liver and delivers the hormone more directly to the uterus. Injections put it straight into the bloodstream or muscle depot. Each path trades one advantage for another, and understanding those tradeoffs helps you know what to expect from your prescription.

Oral Progesterone

Oral micronized progesterone, sold under brand names like Prometrium, is the most commonly prescribed form for menopausal hormone therapy and some menstrual-cycle disorders. “Micronized” means the progesterone particles have been ground very small and suspended in oil (usually peanut oil, worth knowing if you have a nut allergy) to improve absorption from the gut. The molecular structure is identical to what your ovaries produce, which distinguishes it from synthetic progestins like medroxyprogesterone acetate that have a different chemical backbone and can behave differently at hormone receptors.²

The standard approach for protecting the uterine lining during estrogen therapy is 200 mg per day, taken in a cyclic pattern of 12 to 14 days each month, which has been shown to provide adequate endometrial protection for up to five years.³ For other uses, such as hot-flash relief, trials have used 300 mg at bedtime.⁴ The bedtime dosing is deliberate: those liver metabolites, especially allopregnanolone, act on the same brain receptors that sleep medications target. Most people find that oral progesterone makes them sleepy, and taking it at night turns that side effect into something useful.

The flip side of all that liver processing is that oral progesterone produces relatively modest blood levels of the hormone itself. If your provider checks a serum progesterone level while you are on oral capsules, it may read lower than expected. That does not necessarily mean the drug is failing; it means a lot of the progesterone has already been converted in the liver. The clinical effect on the uterine lining can still be adequate even when blood levels look unimpressive.

Vaginal Progesterone

Vaginal progesterone comes in several forms: soft-gel capsules, pessaries (suppositories), and pre-filled gel applicators. It is the preferred route in fertility medicine, and understanding why requires knowing about a phenomenon called the uterine first-pass effect. When progesterone is placed in the vagina, a significant share of it is absorbed directly through the vaginal walls and transported to the uterus without ever entering the general bloodstream. Research has found that uterine tissue concentrations after vaginal administration exceed levels achieved by systemic (injection) routes by more than tenfold, even though blood levels from the injection were seven times higher.⁵ In other words, vaginal delivery is remarkably efficient at getting the hormone where it needs to go for reproductive purposes, while keeping the rest of your body relatively unexposed.

This local targeting has been confirmed more broadly in pharmacokinetic research showing that vaginally administered drugs can achieve high uterine-tissue concentrations with markedly lower plasma levels compared to systemic routes.⁶ For you as a patient, this means vaginal progesterone tends to cause less drowsiness and fewer systemic side effects than the oral form, because less of it circulates through your bloodstream and liver.

Fertility Treatment

In IVF and other assisted reproduction cycles, the ovaries are often suppressed or have just been through egg retrieval, so they cannot produce enough progesterone on their own to support early pregnancy. Supplemental progesterone during the luteal phase is considered an important part of any assisted reproductive technology treatment.⁷ Vaginal forms are the most widely used option in this setting. A randomized trial comparing vaginal pessaries (400 mg twice daily) to vaginal gel (90 mg once daily) found that the pessaries were non-inferior for clinical pregnancy rates, and both were effective and well tolerated.⁸

A trial comparing oral and vaginal progesterone before embryo transfer found similar clinical pregnancy and live-birth rates between routes, even though oral administration produced blood progesterone levels roughly twice as high as the vaginal route.⁹ That finding neatly illustrates the uterine first-pass effect in action: the vaginal route does not need high blood levels to get the job done at the uterus.

Preventing Preterm Birth

Outside of fertility clinics, vaginal progesterone has an established role in reducing preterm birth among women with a short cervix. A landmark trial found that women using daily vaginal progesterone gel had spontaneous delivery before 34 weeks about half as often as those on placebo, with no serious adverse events.¹⁰ Subsequent meta-analyses confirmed that vaginal progesterone significantly reduced the risk of delivery before 32 weeks and lowered rates of combined adverse neonatal outcomes.¹¹ Current evidence-based recommendations support vaginal progesterone when ultrasound shows a cervix measuring 25 mm or shorter before 24 weeks of pregnancy.¹²

Vaginal progesterone does have practical downsides. Many people find the discharge and messiness of suppositories or gels inconvenient, especially over weeks or months of daily use. Vaginal irritation occurs in some users. And the multiple-times-daily dosing schedules common in fertility treatment can feel burdensome compared to swallowing a capsule at bedtime.

Intramuscular Injections

Progesterone in oil, given as an intramuscular injection into the buttock, was the original standard for luteal-phase support in IVF before vaginal options became widely available. It produces high, steady blood levels and does not rely on vaginal absorption, which can be variable. Some clinics still prefer it, and a three-arm trial comparing intramuscular, vaginal, and subcutaneous progesterone during IVF found that the intramuscular group had a higher chemical pregnancy rate (about 42%) than the vaginal (26%) or subcutaneous (28%) groups, though clinical pregnancy rates were not significantly different across routes.¹³

The tradeoff is comfort. Oil-based intramuscular injections are associated with pain and discomfort at the injection site,¹⁴ and that same three-arm trial found significantly more side effects, including local swelling, and significantly lower patient satisfaction in the injection group compared to vaginal or subcutaneous users.¹³ The injections also require a long needle (typically 1.5 inches) reaching deep into muscle, and most people need a partner to administer them. Over weeks of daily shots, the injection sites can develop knots, bruising, and sometimes sterile abscesses. Newer aqueous (water-based) formulations and subcutaneous alternatives are being studied to reduce these problems.

Rectal Progesterone

Rectal suppositories are a less commonly discussed option, but they have pharmacokinetic advantages worth knowing about. A study comparing multiple routes found that the area under the curve during the first eight hours was twice as high with rectal administration compared to other routes, and progesterone levels remained elevated over baseline at 24 hours.¹⁵ Like vaginal delivery, rectal absorption partially bypasses the liver, which contributes to the higher sustained levels.

In clinical practice, rectal progesterone has found a niche as a rescue strategy in frozen embryo transfer cycles. When blood progesterone levels drop below a target threshold before transfer, adding rectal progesterone can bring levels back up. A prospective study found that women who received rectal progesterone as a supplement to their standard vaginal regimen achieved ongoing pregnancy rates comparable to women whose progesterone levels were adequate from the start.¹⁶ The rectal route may also be relevant for people who cannot use vaginal products due to bleeding, infection, or personal preference.

Sublingual Progesterone

Placing a progesterone tablet under your tongue allows it to absorb through the thin mucosa directly into the bloodstream, again bypassing the liver’s first-pass metabolism. At matched doses, sublingual administration produces peak blood levels and overall absorption roughly double what oral swallowing achieves, and the response is more sustained at higher doses.¹⁵ In practice, sublingual progesterone is not widely prescribed in North America or Europe; it appears more often in certain fertility protocols internationally. The taste can be unpleasant, and the tablets must be held under the tongue without swallowing for several minutes to get proper absorption. Some people find this impractical for daily use.

Topical and Transdermal Creams

Progesterone creams applied to the skin are widely available, particularly in over-the-counter formulations marketed for menopause symptoms. However, their clinical usefulness is limited by poor and inconsistent absorption into the bloodstream. A double-blind trial of 2% progesterone cream found that blood levels rose by a statistically significant but very small amount, averaging only about half a nanogram per milliliter above baseline.¹⁷ That level is well below what is considered necessary for endometrial protection or luteal-phase support.

This matters because if you are using estrogen therapy and relying on a progesterone cream to protect your uterine lining, you may not be getting adequate protection. Transdermal progesterone can accumulate in the fat layer under the skin, creating a depot that slowly releases hormone, but the amount reaching the uterus is unpredictable. Most professional guidelines do not endorse topical progesterone cream as a substitute for oral or vaginal progesterone when endometrial protection is the goal.

Understanding Blood Levels Across Routes

One of the most confusing aspects of progesterone therapy is that blood levels do not always predict how well the treatment is working. A small study comparing oral and vaginal administration of micronized progesterone found that vaginal delivery produced significantly higher serum progesterone levels overall (about 8.3 versus 5.1 ng/mL), with the difference becoming more pronounced when estrogen levels were above 30 pg/mL.¹⁸ Yet clinical outcomes like pregnancy rates and endometrial changes do not always track neatly with these blood-level differences, because vaginal progesterone delivers so much of its dose directly to the uterus without it ever showing up in a blood draw.

If your provider orders a serum progesterone test while you are on vaginal progesterone, a “low” number does not necessarily mean your uterus is under-exposed. Conversely, a reassuringly high number on oral progesterone may partly reflect metabolites that the standard blood test cannot always distinguish from the parent hormone. Discuss any lab results in the context of which route you are using, because the interpretation changes.

Compounded Versus FDA-Approved Products

You may encounter progesterone from compounding pharmacies, which custom-mix hormones into capsules, creams, troches (lozenges), or suppositories. A systematic review found that absorption trends from compounded bioidentical products were generally consistent with published data from FDA-approved versions.¹⁹ The concern with compounded products, however, is quality control. Unlike FDA-approved drugs, compounded hormones are not routinely tested by any regulatory agency for potency, purity, or contamination. An analysis of compounded pharmacy products found that because the dose ratio of estrogen to progesterone critically affects endometrial safety, improperly formulated combinations could have serious consequences, including increased risk of endometrial cancer.²⁰

This does not mean compounded progesterone is always dangerous. There are situations where compounding is medically necessary, such as when you need a dose or formulation not commercially available, or when you have an allergy to an inactive ingredient in the brand-name product (the peanut oil in Prometrium is a common example). But if an FDA-approved option works for your situation, it offers a more predictable product with established quality standards.

Drug Interactions and Liver Metabolism

Progesterone is broken down in part by a liver enzyme family called CYP3A4, one of the busiest drug-metabolizing systems in your body. This means medications that rev up CYP3A4 activity, such as certain anti-seizure drugs, rifampin (an antibiotic used for tuberculosis), and the herbal supplement St. John’s wort, can speed up progesterone clearance and potentially reduce its effectiveness. Research into related progestins has confirmed that strong CYP3A4 inducers significantly lower circulating hormone levels.²¹

Interestingly, the interaction works in both directions. Progesterone itself can alter how CYP3A4 processes other drugs. Laboratory studies have shown that progesterone acts as an allosteric modulator of CYP3A4, meaning it changes the shape of the enzyme’s active site and affects how quickly other medications are broken down.²² In practical terms, this is most relevant for people taking certain antibiotics (particularly macrolides) or medications with narrow therapeutic windows. If you start or stop progesterone, mention it to any provider prescribing new medications.

Routes that bypass the liver, particularly vaginal and rectal, are less affected by CYP3A4-related interactions because less of the hormone passes through the liver in the first place. This is another reason vaginal progesterone may be preferred in people taking medications known to induce liver enzymes.

Choosing Between Oral and Vaginal for Menopause

For menopausal hormone therapy, the choice between oral and vaginal progesterone often comes down to what you are trying to achieve and which side effects you tolerate better. If you struggle with insomnia (a common menopause symptom), the sedating effect of oral progesterone at bedtime can be a genuine benefit rather than just a tolerated side effect. Oral micronized progesterone at 200 mg per day for 12 to 14 days per cycle has a strong track record for protecting the uterine lining during estrogen therapy.³

If you find that oral progesterone makes you excessively groggy, causes bloating or mood changes, or if you are on a medication that strongly induces CYP3A4, vaginal progesterone may be a better fit. The vaginal route delivers more progesterone directly to the uterus with fewer systemic metabolites, which generally means fewer brain-fog or sedation complaints. The tradeoff, again, is the inconvenience and messiness of vaginal application.

Subcutaneous Injections and Emerging Options

Subcutaneous progesterone, injected just under the skin rather than deep into muscle, is a newer option gaining traction in fertility clinics. It uses a shorter needle, can be self-administered more easily, and in the three-arm trial discussed above, produced patient satisfaction comparable to the vaginal route and significantly higher than intramuscular injections.¹³ Aqueous (water-based) formulations are being developed as alternatives to the thick oil-based intramuscular preparations, which tend to cause more injection-site reactions.¹⁴ These newer formulations are not yet universally available, but they represent a meaningful improvement for people who need injectable progesterone and dread the daily oil shots.

Longer-acting progesterone delivery systems, including vaginal rings and extended-release implants, are in various stages of research. The goal is to reduce dosing frequency while maintaining steady hormone levels, a challenge given progesterone’s relatively short half-life in the body. For now, though, daily dosing in one form or another remains the norm regardless of which route you use.